Duchenne Muscular Dystrophy Market Report 2026
Download Free Sample Buy Now
Duchenne Muscular Dystrophy Market Global Report 2026 Market Report Infographic Image
Item added to cart!

Published : February 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF
Purchase This Report

Duchenne Muscular Dystrophy Market Report 2026

Global Outlook – By Therapy (Mutation Suppression, Exon Skipping Approach), By Therapeutic Class (Molecular Based Therapies, Steroid Therapy), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By End User (Hospitals, Homecare, Specialty Clinics, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Duchenne Muscular Dystrophy Market Overview

• Duchenne Muscular Dystrophy market size has reached to $1.25 billion in 2025

• Expected to grow to $1.87 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%

• Growth Driver: Rising Prevalence Of Chronic Diseases Fuels Growth In The Duchenne Muscular Dystrophy Market

• Market Trend: Technological Advancements In Clinical Trial Simulator Boost Duchenne Muscular Dystrophy Market

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Duchenne Muscular Dystrophy Market?

Duchenne muscular dystrophy is a genetic disease that causes gradual muscle loss, affecting the skeletal, cardiac, and lung muscles. It is caused by a mutation in the gene responsible for producing dystrophin, a protein that is crucial for the healthy operation of muscles.

The main types of therapies included in duchenne muscular dystrophy are mutation suppression and exon skipping approach. Exon skipping is the most prevalent type of alternative splicing, in which introns and intervals on a pre-mRNA molecule that ordinarily function as exons of a gene are removed together when a final mRNA is formed. therapeutic classes included are molecular-based therapies and steroid therapy and the route of administration are oral, parenteral, and others. These are distributed through hospital pharmacies, online pharmacies, and retail pharmacies for use in end-users such as hospitals, homecare, specialty clinics, and others.

Duchenne Muscular Dystrophy Market Global Report 2026 Market Report bar graph

What Is The Duchenne Muscular Dystrophy Market Size and Share 2026?

The duchenne muscular dystrophy market size has grown strongly in recent years. It will grow from $1.25 billion in 2025 to $1.35 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing prevalence of duchenne muscular dystrophy, advancements in molecular biology techniques, rising awareness about rare genetic disorders, development of early diagnostic tools, increasing research collaborations between academic and pharmaceutical institutions.

What Is The Duchenne Muscular Dystrophy Market Growth Forecast?

The duchenne muscular dystrophy market size is expected to see strong growth in the next few years. It will grow to $1.87 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to growth in gene therapy adoption, expansion of precision medicine approaches, increased investment in rare disease drug development, regulatory incentives for orphan drugs, integration of digital health solutions in patient management. Major trends in the forecast period include gene editing advancements, personalized treatment protocols, rare disease research funding, patient-centric care models, orphan drug development.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Duchenne Muscular Dystrophy Market Segmentation

1) By Therapy: Mutation Suppression, Exon Skipping Approach

2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Mutation Suppression: Antisense Oligonucleotides (ASOs), Small Molecules, Gene Therapy

2) By Exon Skipping Approach: Exon-Skipping Therapies, Combination Therapies, Clinical Trials And Investigational Drugs

What Is The Driver Of The Duchenne Muscular Dystrophy Market?

The increasing prevalence of chronic diseases is expected to propel the growth of the Duchenne muscular dystrophy market in the future. A chronic disease is a health issue or condition with long-lasting symptoms lasting for at least a year. The Duchenne muscular dystrophy contributes to the prevalence of chronic diseases by addressing the specific therapeutic needs of individuals with this genetic disorder, highlighting the broader significance of personalized medicine in managing and potentially mitigating the impact of chronic conditions. For instance, in January 2023, according to the National Library of Medicine, a US-based government agency, the number of people in the US aged 50 and older who have at least 1 chronic condition would increase to 142.66 million by 2050. Therefore, the increasing prevalence of chronic diseases is driving the growth of the Duchenne muscular dystrophy industry.

Key Players In The Global Duchenne Muscular Dystrophy Market

Major companies operating in the duchenne muscular dystrophy market are Pfizer Inc., GlaxoSmithKline plc, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc., WAVE Life Sciences Ltd.

Global Duchenne Muscular Dystrophy Market Trends and Insights

Major companies operating in the Duchenne muscular dystrophy market are developing technological advancements, such as clinical trial design, to enhance the efficiency and effectiveness of drug development processes, improve patient outcomes, and accelerate the approval of new therapies. Clinical trial design is the process of organizing and planning a clinical trial to evaluate a new treatment's safety and effectiveness, including defining goals, selecting participants, and outlining methods and analyses. For instance, in March 2024, Critical Path Institute (C-Path), a US-based non-profit organization, launched the DMD Clinical Trial Simulator (CTS). This innovative tool, developed by C-Path's Duchenne Regulatory Science Consortium, aims to optimize the design of efficacy studies for DMD therapies. Key features of the CTS include advanced modeling of functional test performance, the capability to simulate various scenarios, increased efficiency in trial design, and public accessibility via the C-Path website and the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). As such, it serves as a valuable resource for researchers and pharmaceutical companies engaged in DMD research.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Duchenne Muscular Dystrophy Market?

In October 2025, Novartis AG., a Switzerland-based global pharmaceutical company, acquired Avidity Biosciences, Inc., for $12 billion in cash. With this acquisition, Novartis aims to expand its RNA-targeted therapies portfolio, accelerate its presence in genetic disease treatments, and enhance its ability to develop innovative medicines for patients with serious and rare conditions. Avidity Biosciences, Inc., is a US-based biotechnology company that developing a treatment for Duchenne Muscular Dystrophy (DMD) called del-zota.

Regional Insights

North America was the largest region in the Duchenne muscular dystrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Duchenne Muscular Dystrophy Market?

The duchenne muscular dystrophy market includes revenues earned by entities by providing respiratory therapy, physical therapy and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Duchenne Muscular Dystrophy Market Report 2026?

The duchenne muscular dystrophy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the duchenne muscular dystrophy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Duchenne Muscular Dystrophy Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $1.35 billion
Revenue Forecast In 2035 $1.87 billion
Growth Rate CAGR of 7.9% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Therapy, Therapeutic Class, Route Of Administration, Distribution Channel, End User
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Pfizer Inc., GlaxoSmithKline plc, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma In
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Duchenne Muscular Dystrophy Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Duchenne Muscular Dystrophy Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Duchenne Muscular Dystrophy Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Duchenne Muscular Dystrophy Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Gene Editing Advancements

4.2.2 Personalized Treatment Protocols

4.2.3 Rare Disease Research Funding

4.2.4 Patient-Centric Care Models

4.2.5 Orphan Drug Development

5. Duchenne Muscular Dystrophy Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Homecare

5.4 Research Institutes

5.5 Rehabilitation Centers

6. Duchenne Muscular Dystrophy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Duchenne Muscular Dystrophy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Duchenne Muscular Dystrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Duchenne Muscular Dystrophy Market Size, Comparisons And Growth Rate Analysis

7.3. Global Duchenne Muscular Dystrophy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Duchenne Muscular Dystrophy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Duchenne Muscular Dystrophy Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Duchenne Muscular Dystrophy Market Segmentation

9.1. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Mutation Suppression, Exon Skipping Approach

9.2. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Molecular Based Therapies, Steroid Therapy

9.3. Global Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral, Parenteral, Other Routes Of Administration

9.4. Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

9.5. Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Homecare, Specialty Clinics, Other End-Users

9.6. Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Mutation Suppression, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Antisense Oligonucleotides (ASOs), Small Molecules, Gene Therapy

9.7. Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Exon Skipping Approach, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Exon-Skipping Therapies, Combination Therapies, Clinical Trials And Investigational Drugs

10. Duchenne Muscular Dystrophy Market Regional And Country Analysis

10.1. Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Duchenne Muscular Dystrophy Market

11.1. Asia-Pacific Duchenne Muscular Dystrophy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Duchenne Muscular Dystrophy Market

12.1. China Duchenne Muscular Dystrophy Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Duchenne Muscular Dystrophy Market

13.1. India Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Duchenne Muscular Dystrophy Market

14.1. Japan Duchenne Muscular Dystrophy Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Duchenne Muscular Dystrophy Market

15.1. Australia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Duchenne Muscular Dystrophy Market

16.1. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Duchenne Muscular Dystrophy Market

17.1. South Korea Duchenne Muscular Dystrophy Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Duchenne Muscular Dystrophy Market

18.1. Taiwan Duchenne Muscular Dystrophy Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Duchenne Muscular Dystrophy Market

19.1. South East Asia Duchenne Muscular Dystrophy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Duchenne Muscular Dystrophy Market

20.1. Western Europe Duchenne Muscular Dystrophy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Duchenne Muscular Dystrophy Market

21.1. UK Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Duchenne Muscular Dystrophy Market

22.1. Germany Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Duchenne Muscular Dystrophy Market

23.1. France Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Duchenne Muscular Dystrophy Market

24.1. Italy Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Duchenne Muscular Dystrophy Market

25.1. Spain Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Duchenne Muscular Dystrophy Market

26.1. Eastern Europe Duchenne Muscular Dystrophy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Duchenne Muscular Dystrophy Market

27.1. Russia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Duchenne Muscular Dystrophy Market

28.1. North America Duchenne Muscular Dystrophy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Duchenne Muscular Dystrophy Market

29.1. USA Duchenne Muscular Dystrophy Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Duchenne Muscular Dystrophy Market

30.1. Canada Duchenne Muscular Dystrophy Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Duchenne Muscular Dystrophy Market

31.1. South America Duchenne Muscular Dystrophy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Duchenne Muscular Dystrophy Market

32.1. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Duchenne Muscular Dystrophy Market

33.1. Middle East Duchenne Muscular Dystrophy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Duchenne Muscular Dystrophy Market

34.1. Africa Duchenne Muscular Dystrophy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Duchenne Muscular Dystrophy Market Regulatory and Investment Landscape

36. Duchenne Muscular Dystrophy Market Competitive Landscape And Company Profiles

36.1. Duchenne Muscular Dystrophy Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Duchenne Muscular Dystrophy Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Duchenne Muscular Dystrophy Market Company Profiles

36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

36.3.3. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Duchenne Muscular Dystrophy Market Other Major And Innovative Companies

Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc.

38. Global Duchenne Muscular Dystrophy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Market

40. Duchenne Muscular Dystrophy Market High Potential Countries, Segments and Strategies

40.1 Duchenne Muscular Dystrophy Market In 2030 - Countries Offering Most New Opportunities

40.2 Duchenne Muscular Dystrophy Market In 2030 - Segments Offering Most New Opportunities

40.3 Duchenne Muscular Dystrophy Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Duchenne Muscular Dystrophy Market, Overview Of Key Products - Product Examples
  • Table 2: Global Duchenne Muscular Dystrophy Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Duchenne Muscular Dystrophy Market, Supply Chain Analysis
  • Table 4: Global Duchenne Muscular Dystrophy Market, Major Raw Material Providers
  • Table 5: Global Duchenne Muscular Dystrophy Market, Major Resource Providers
  • Table 6: Global Duchenne Muscular Dystrophy Market, Major Manufacturers (Suppliers)
  • Table 7: Global Duchenne Muscular Dystrophy Market, Major Distributors And Channel Partners
  • Table 8: Global Duchenne Muscular Dystrophy Market, Key Technologies & Future Trends
  • Table 9: Global Duchenne Muscular Dystrophy Market, Major Trends
  • Table 10: Global Duchenne Muscular Dystrophy Market, Major End Users
  • Table 11: Global Duchenne Muscular Dystrophy Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Duchenne Muscular Dystrophy Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Duchenne Muscular Dystrophy Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Duchenne Muscular Dystrophy Market - TAM, US$ Billion, 2025
  • Table 15: Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Mutation Suppression, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Exon Skipping Approach, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: China, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: India, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: Taiwan, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: South East Asia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: UK, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: France, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: North America, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: USA, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: South America, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Global Duchenne Muscular Dystrophy Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 97: Global Duchenne Muscular Dystrophy Market - Company Scoring Matrix
  • Table 98: Pfizer Inc. Financial Performance
  • Table 99: GlaxoSmithKline plc Financial Performance
  • Table 100: BioMarin Pharmaceutical Inc. Financial Performance
  • Table 101: Sarepta Therapeutics Inc. Financial Performance
  • Table 102: PTC Therapeutics Inc. Financial Performance
  • Table 103: Global Duchenne Muscular Dystrophy Market, Competitive Benchmarking (In USD Billions)
  • Table 104: Global Duchenne Muscular Dystrophy Market, Competitive Dashboard
  • Table 105: Global Duchenne Muscular Dystrophy Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 106: Global, Duchenne Muscular Dystrophy Market Size Gain ($ Billion), Segmentation By Therapy, 2025 – 2030
  • Table 107: Global, Duchenne Muscular Dystrophy Market Size Gain ($ Billion), Segmentation By Therapeutic Class, 2025 – 2030
  • Table 108: Global, Duchenne Muscular Dystrophy Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030

List Of Figures

    Figure 1: Global Duchenne Muscular Dystrophy Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Duchenne Muscular Dystrophy Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Duchenne Muscular Dystrophy Market, Supply Chain Analysis
  • Figure 4: Global Duchenne Muscular Dystrophy Market, Major Raw Material Providers
  • Figure 5: Global Duchenne Muscular Dystrophy Market, Major Resource Providers
  • Figure 6: Global Duchenne Muscular Dystrophy Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Duchenne Muscular Dystrophy Market, Major Distributors And Channel Partners
  • Figure 8: Global Duchenne Muscular Dystrophy Market, Key Technologies & Future Trends
  • Figure 9: Global Duchenne Muscular Dystrophy Market, Major Trends
  • Figure 10: Global Duchenne Muscular Dystrophy Market, Major End Users
  • Figure 11: Global Duchenne Muscular Dystrophy Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Duchenne Muscular Dystrophy Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Duchenne Muscular Dystrophy Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Duchenne Muscular Dystrophy Market - TAM, US$ Billion, 2025
  • Figure 15: Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Mutation Suppression, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Exon Skipping Approach, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: China, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: India, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: Taiwan, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: South East Asia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: UK, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: France, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: North America, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: USA, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: South America, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Global Duchenne Muscular Dystrophy Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 97: Global Duchenne Muscular Dystrophy Market - Company Scoring Matrix
  • Figure 98: Pfizer Inc. Financial Performance
  • Figure 99: GlaxoSmithKline plc Financial Performance
  • Figure 100: BioMarin Pharmaceutical Inc. Financial Performance
  • Figure 101: Sarepta Therapeutics Inc. Financial Performance
  • Figure 102: PTC Therapeutics Inc. Financial Performance
  • Figure 103: Global Duchenne Muscular Dystrophy Market, Competitive Benchmarking (In USD Billions)
  • Figure 104: Global Duchenne Muscular Dystrophy Market, Competitive Dashboard
  • Figure 105: Global Duchenne Muscular Dystrophy Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 106: Global, Duchenne Muscular Dystrophy Market Size Gain ($ Billion), Segmentation By Therapy, 2025 – 2030
  • Figure 107: Global, Duchenne Muscular Dystrophy Market Size Gain ($ Billion), Segmentation By Therapeutic Class, 2025 – 2030
  • Figure 108: Global, Duchenne Muscular Dystrophy Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030

Parathyroid Disease Treatment Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Parathyroid Disease Treatment Market Revenue Outlook: Strategic Insights and Forecast to 2029

Industry Forecast: PCSK9 Inhibitor Market to Generate $6.87 Billion Revenue by 2029

Read More About Industry Forecast: PCSK9 Inhibitor Market to Generate $6.87 Billion Revenue by 2029

CAGR of 5.4% Projected for Pediatric Asthma Treatment Market From 2025 to 2029

Read More About CAGR of 5.4% Projected for Pediatric Asthma Treatment Market From 2025 to 2029

Latest Market Developments in Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Industry: Forecast 2025–2029

Read More About Latest Market Developments in Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Industry: Forecast 2025–2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Musculoskeletal Disorders Drugs Global Market Report 2022 – By Type (Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmaci...

Duchenne Muscular Dystrophy Market Report 2026 - Global Outlook – By Therapy (Mutation Suppression, Exon Skipping Approach), By Therapeutic Class (Molecular Based Therapies, Steroid Therapy), By Route Of Administration (...

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report 2026 - Global Outlook – By Type (Small Molecules, Biologics), By Distribution Channel (Offline, Online), By Application (Hospitals, Clinics, Home Care) - Marke...

Muscle Wasting Disorders Market Report 2026 - Global Outlook – By Treatment Type (Medications, Physical Therapy, Nutritional Therapy, Surgery, Gene Therapy, Other Treatment Types), By Disorder Type (Muscular Dystrophy, A...

Muscle Tension Dysphonia Treatment Market Report 2026 - Global Outlook – By Treatment Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Analgesics, Voice Therapy, Behavioral Counseling), By Age Group (Pediatrics, Adul...

Muscle Spasticity Market Report 2026 - Global Outlook – By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Other Drugs), By Route Of Administration (Oral, Intramuscular, Other Routes Of Administrations...

Vitamin D Therapy Market Report 2026 - Global Outlook – By Administration (Oral, Parenteral), By Purchasing (OTC Drugs, Prescription Drugs), By Age Group (Children, Adults, Senior Adults), By Application (Osteoporosis, R...

Muscle Pain Treatment Market Report 2026 - Global Outlook – By Pharmacological Treatment (Analgesics, Muscle Relaxants, Topical Analgesics, Other Pharmacological Treatments), By Non-Pharmacological Treatment (Physical Th...

Frequently Asked Questions

The Duchenne Muscular Dystrophy market was valued at $1.25 billion in 2025, increased to $1.35 billion in 2026, and is projected to reach $1.87 billion by 2030.

The global Duchenne Muscular Dystrophy market is expected to grow at a CAGR of 8.5% from 2026 to 2035 to reach $1.87 billion by 2035.

Some Key Players in the Duchenne Muscular Dystrophy market Include, Pfizer Inc., GlaxoSmithKline plc, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc., WAVE Life Sciences Ltd. .

Major trend in this market includes: Technological Advancements In Clinical Trial Simulator Boost Duchenne Muscular Dystrophy Market. For further insights on this market. request a sample here

North America was the largest region in the Duchenne muscular dystrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us